-
ESTABLISHING A LEADER IN CELL-BASED IMMUNOTHERAPIES BUILT ON DECADES OF EXPERTISE IN THE FIELD OF ALLOGENEIC DENDRITIC CELL BIOLOGY
Immunicum is listed on NASDAQ Stockholm under the ticker IMMU
About us
Developing innovative cancer immunotherapies
Immunicum is advancing novel cell-based approaches to treat blood-borne and solid tumors.
Learn more
Press Releases
Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics
05 Jan 2022Immunicum to Participate in Upcoming Investor and Industry Conferences in January
03 Jan 2022Immunicum Publishes Year-End Letter by CEO and Announces Upcoming Shareholder Event to Present Pipeline Outlook
21 Dec 2021
News
-
2021 CEO Year-End Letter
21 Dec 2021 -
2021 ASH Annual Meeting – Posters
20 Dec 2021 -
European Hematology Association (EHA) 2021 Virtual Meeting – Posters
11 Jun 2021 -
Immunicum Corporate Presentation at Redeye Growth Day 2021
8 Jun 2021 -
Immunicum Investor Event on April 22, 2021 at 1:00 pm CET
19 Apr 2021
